These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Optimization of Allosteric With-No-Lysine (WNK) Kinase Inhibitors and Efficacy in Rodent Hypertension Models. Yamada K; Levell J; Yoon T; Kohls D; Yowe D; Rigel DF; Imase H; Yuan J; Yasoshima K; DiPetrillo K; Monovich L; Xu L; Zhu M; Kato M; Jain M; Idamakanti N; Taslimi P; Kawanami T; Argikar UA; Kunjathoor V; Xie X; Yagi YI; Iwaki Y; Robinson Z; Park HM J Med Chem; 2017 Aug; 60(16):7099-7107. PubMed ID: 28771350 [TBL] [Abstract][Full Text] [Related]
3. Bidirectional Allosteric Communication between the ATP-Binding Site and the Regulatory PIF Pocket in PDK1 Protein Kinase. Schulze JO; Saladino G; Busschots K; Neimanis S; Süß E; Odadzic D; Zeuzem S; Hindie V; Herbrand AK; Lisa MN; Alzari PM; Gervasio FL; Biondi RM Cell Chem Biol; 2016 Oct; 23(10):1193-1205. PubMed ID: 27693059 [TBL] [Abstract][Full Text] [Related]
4. WNK1-OSR1 kinase-mediated phospho-activation of Na+-K+-2Cl- cotransporter facilitates glioma migration. Zhu W; Begum G; Pointer K; Clark PA; Yang SS; Lin SH; Kahle KT; Kuo JS; Sun D Mol Cancer; 2014 Feb; 13():31. PubMed ID: 24555568 [TBL] [Abstract][Full Text] [Related]
5. Development of WNK signaling inhibitors as a new class of antihypertensive drugs. Ishigami-Yuasa M; Watanabe Y; Mori T; Masuno H; Fujii S; Kikuchi E; Uchida S; Kagechika H Bioorg Med Chem; 2017 Jul; 25(14):3845-3852. PubMed ID: 28566208 [TBL] [Abstract][Full Text] [Related]
6. 4-Substituted-7-azaindoles bearing a ureidobenzofuranone moiety as potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR). Tsou HR; MacEwan G; Birnberg G; Zhang N; Brooijmans N; Toral-Barza L; Hollander I; Ayral-Kaloustian S; Yu K Bioorg Med Chem Lett; 2010 Apr; 20(7):2259-63. PubMed ID: 20188551 [TBL] [Abstract][Full Text] [Related]
7. Kinetic mechanism and inhibitor characterization of WNK1 kinase. Yagi YI; Abe K; Ikebukuro K; Sode K Biochemistry; 2009 Nov; 48(43):10255-66. PubMed ID: 19739668 [TBL] [Abstract][Full Text] [Related]
8. Discovery of a Selective and Potent Inhibitor of Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 (MNK1/2) Utilizing Structure-Based Drug Design. Han W; Ding Y; Xu Y; Pfister K; Zhu S; Warne B; Doyle M; Aikawa M; Amiri P; Appleton B; Stuart DD; Fanidi A; Shafer CM J Med Chem; 2016 Apr; 59(7):3034-45. PubMed ID: 27002243 [TBL] [Abstract][Full Text] [Related]
9. Structure-based lead identification of ATP-competitive MK2 inhibitors. Barf T; Kaptein A; de Wilde S; van der Heijden R; van Someren R; Demont D; Schultz-Fademrecht C; Versteegh J; van Zeeland M; Seegers N; Kazemier B; van de Kar B; van Hoek M; de Roos J; Klop H; Smeets R; Hofstra C; Hornberg J; Oubrie A Bioorg Med Chem Lett; 2011 Jun; 21(12):3818-22. PubMed ID: 21565500 [TBL] [Abstract][Full Text] [Related]
10. Conformation constraint of anilides enabling the discovery of tricyclic lactams as potent MK2 non-ATP competitive inhibitors. Xiao D; Palani A; Huang X; Sofolarides M; Zhou W; Chen X; Aslanian R; Guo Z; Fossetta J; Tian F; Trivedi P; Spacciapoli P; Whitehurst CE; Lundell D Bioorg Med Chem Lett; 2013 Jun; 23(11):3262-6. PubMed ID: 23602398 [TBL] [Abstract][Full Text] [Related]